RestorLife Med review

What it is

RestorLife Med is a physician-guided telehealth practice founded by Dr. Michael Wasef, MD, described as board-certified in internal medicine and licensed in all 50 states. Its catalogue is organised in three bands: hormone therapy (estradiol as patch, gel or oral tablet, and oral progesterone), anti-aging (sermorelin, positioned as a natural complement to hormone therapy), and weight loss (compounded semaglutide and tirzepatide in full and microdose entry protocols, compounded with B12 and including a free quarterly blood test on the GLP-1 protocols). Medication is stated as sourced from FDA-regulated, state-licensed US compounding pharmacies, and every patient is evaluated by a physician who prescribes only if treatment is appropriate.

How it works

Storefront-first with a clinical review behind it, and unusually generous on the support side: physician consultation and ongoing review, free priority shipping in discreet packaging, a personalised dosing protocol, monthly check-ins with dose adjustments, and unlimited messaging with the care team are listed as included on every plan card, including the sermorelin card. Delivery is described as roughly 48 hours by priority shipping across all 50 states. The identity layer is stronger than most: the founder is named with his specialty and licensure, LegitScript certification is displayed with a seal ID that verifies rather than a badge image, and coverage is stated as all 50 states rather than confirmed at intake. What is not disclosed is the pharmacy — medications are described only as coming from FDA-regulated, state-licensed US compounding pharmacies, with no partner named. Pricing presentation is worth reading carefully too. Its hormone-therapy cards carry a first-order-only 50% discount code, and its GLP-1 cards carry a 50%-off-first-month badge; the sermorelin card carries neither, showing $149 and $99 against struck-through $299 and $166 figures with no promotional qualifier, so those appear to be standing rates rather than introductory ones. Confirm that at checkout — a first-order-only rate presented as a standing rate is the most common way a plan looks cheaper than it is.

Pricing transparency

Sermorelin is $149 a month on the one-month plan and $99 a month on the three-month plan, listed against compare-at figures of $299 and $166. What that buys is stated: the physician consultation and ongoing review, free priority discreet shipping, monthly check-ins and dosage adjustments, and unlimited care-team messaging. The three-month rate is the lowest sermorelin figure in this batch. Two things to establish before you commit. First, no dose, vial size or injection frequency is published beside the price, so "a month" of sermorelin is undefined in volume terms — that is the variable that actually differs between vendors, and it is the question to ask. Second, confirm that $149 is the ongoing rate rather than a first-order price, since the surrounding hormone and GLP-1 cards on the same page do carry first-order-only qualifiers. On the weight-loss side, semaglutide is $299 a month with the first month at $149 and $199 a month on a six-month plan, tirzepatide $399 with the first month at $199 and $265 on six months, and microdose entry tiers sit lower — those are GLP-1 figures and are not a peptide price.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. RestorLife states in its own copy that compounded medications are not FDA-approved as finished products and that its pharmacies are FDA-regulated and state-licensed, but it does not name them, and compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, there is only one peptide here to assess. Sermorelin is a growth-hormone-releasing hormone analogue: it acts on the pituitary to release your own growth hormone rather than supplying exogenous hormone, which keeps the somatostatin feedback loop intact and is the meaningful mechanistic difference from injected HGH. That mechanism is real and well characterised. What is thin is the long-term human outcome data — short-term rises in GH and IGF-1 are measurable, and the recovery, sleep and lean-body-composition claims the category is sold on do not rest on controlled outcome trials at that level. The site's framing of sermorelin as a complement to hormone therapy is at least honest about it being an adjunct rather than a headline treatment. Individual results vary.

Pros and watch-outs

The evidence behind what RestorLife Med prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

How RestorLife Med compares

A few alternatives worth a look, depending on what you’re optimizing for.

• RHRevel Health

  Comparing injected against intranasal NAD⁺ at two published prices in one place

  See Revel Health →
• RRRewinding RX

  NAD⁺ buyers who want concentration, vial size and a dosing ladder published with the price

  See Rewinding RX →
• REREMEVi

  Choosing between injected, nasal and oral NAD⁺ without the price changing

  See REMEVi →